High-throughput behavioral screen in C. elegans reveals Parkinson's disease drug candidates.
Salman SohrabiDanielle E MorRachel KaletskyWilliam KeyesColeen T MurphyPublished in: Communications biology (2021)
We recently linked branched-chain amino acid transferase 1 (BCAT1) dysfunction with the movement disorder Parkinson's disease (PD), and found that RNAi-mediated knockdown of neuronal bcat-1 in C. elegans causes abnormal spasm-like 'curling' behavior with age. Here we report the development of a machine learning-based workflow and its application to the discovery of potentially new therapeutics for PD. In addition to simplifying quantification and maintaining a low data overhead, our simple segment-train-quantify platform enables fully automated scoring of image stills upon training of a convolutional neural network. We have trained a highly reliable neural network for the detection and classification of worm postures in order to carry out high-throughput curling analysis without the need for user intervention or post-inspection. In a proof-of-concept screen of 50 FDA-approved drugs, enasidenib, ethosuximide, metformin, and nitisinone were identified as candidates for potential late-in-life intervention in PD. These findings point to the utility of our high-throughput platform for automated scoring of worm postures and in particular, the discovery of potential candidate treatments for PD.
Keyphrases
- high throughput
- deep learning
- machine learning
- convolutional neural network
- neural network
- single cell
- randomized controlled trial
- amino acid
- artificial intelligence
- big data
- small molecule
- electronic health record
- resistance training
- emergency department
- oxidative stress
- human health
- risk assessment
- high resolution
- quantum dots
- mass spectrometry